Group 1 - The core product HECN30227 is a first-in-class drug developed by the company, targeting both cccDNA and intDNA sources of hepatitis B surface antigen (HBsAg) with global intellectual property rights [1] - Preclinical data indicates that HECN30227 exhibits pan-genotypic activity, effectively reducing HBsAg levels and maintaining efficacy against nucleoside drug-resistant strains, outperforming clinical competitors in both in vitro and in vivo efficacy [1] - HECN30227 utilizes the company's unique HEC-GalNova liver-targeted delivery system, achieving precise and efficient liver delivery while significantly reducing off-target risks [1] Group 2 - Since 2022, the company has entered the small nucleic acid field, establishing a comprehensive R&D platform covering target discovery, sequence design and synthesis, chemical modification, delivery technology, and biological evaluation, positioning itself among the top tier in China [2] - The company has applied for over 50 patents and developed more than 10 small nucleic acid pipelines across four major areas: anti-infection, cardiovascular-kidney-metabolism, respiratory system, and oncology, with plans to advance multiple small nucleic acid drugs into clinical stages annually [2] - The company is leading the innovation wave in China's small nucleic acid drugs through a multi-faceted approach of "technology + pipeline + industrialization," aiming to address unmet clinical needs and provide globally competitive "China-made" treatment solutions [2]